Table 1. Patient characteristics.
| Characteristic | Denosumab (n=13) | Combination (n=17) | P-value |
|---|---|---|---|
| Age/years | 75.1±1.8 | 75.5±1.4 | P=0.841 3 |
| BMI/(kg·m−2) | 20.9±0.9 | 21.4±1.0 | P=0.717 1 |
| Serum corrected Ca/(mg·dL−1) | 9.0±0.1 | 9.0±0.1 | P=0.917 5 |
| Serum phosphorus/(mg·dL−1) | 3.8±0.1 | 3.7±0.1 | P=0.825 4 |
| Serum BAP/(μg·L−1) | 21.6±2.5 | 19.2±2.4 | P=0.497 6 |
| Serum TRACP-5b/(mU·dL−1) | 587.5±33.5 | 571.5±48.8 | P=0.788 6 |
| Urinary NTX (nmol BCE per mmol CRE) | 60.4±9.1 | 66.0±8.0 | P=0.644 0 |
| 1, 25 (OH)2D3/(pg·mL−1) | 56.1±5.6 | 58.2±4.3 | P=0.773 4 |
| Serum whole PTH/(pg·mL−1) | 35.7±2.8 | 28.7±3.4 | P=0.126 7 |
| L1–4 BMD/(g·cm−2) | 0.799±0.03 | 0.730±0.03 | P=0.153 0 |
| Total hip BMD/(g·cm−2) | 0.64±0.03 | 0.62±0.01 | P=0.456 3 |
BAP, bone-specific alkaline phosphatase; BMD, bone mineral density; BMI, body mass index; NTX, N-terminal telopeptides of type I collagen; PTH, parathyroid hormone; TRACP, tartrate-resistant acid phosphatase.
Results are expressed as mean±s.e.
Differences of P<0.05 were considered significant.